Efficacy and safety of lanreotide autogel compared with lanreotide 40  mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN)

Lanreotide autogel is a somatostatin analog (SSA) approved for the treatment of acromegaly in 73 countries worldwide; however, it is not yet approved in China. The aim of this study was to evaluate the efficac...

Source: BMC Endocrine Disorders - May 4, 2020 Category: Endocrinology Authors: Zhenmei An, Ting Lei, Lian Duan, Pei Hu, Zhongping Gou, Lihui Zhang, Lucie Durand-Gasselin, Nan Wang, Yan Wang and Feng Gu Tags: Research article Source Type: research